CompletedNot Applicable

Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

Denmark260 participantsStarted 2013-02

Plain-language summary

The investigators will analyze biomarkers related to the prognosis and treatment of necrotizing soft tissue infections (NSTI). The focus will be on whether certain endothelial and immune system biomarkers can function as markers of disease severity, mortality as well as the effects of hyperbaric oxygen therapy (HBOT). Biomarkers will be measured upon admission to an intensive care unit at Copenhagen University Hospital and during the following 3 days.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria for NSTI patients (both of which must be met): * Diagnosed with NSTI based on surgical findings (necrosis of any soft tissue compartment; dermis, hypodermis, fascia or muscle) * Admitted to the Intensive Care Unit (ICU) and/or operated for NSTI at Copenhagen University Hospital Exclusion Criteria for NSTI patients: * They are categorized as non NSTI in the operating theatre Inclusion criteria for orthopaedic control patients: * Undergoing elective orthopedic surgery (non-pathological fractures, joint replacement surgery or spine surgery) at Copenhagen University Hospital Exclusion criteria for orthopaedic control patients: * Ongoing infection or inflammatory condition

What they're measuring

sTM and sE-selectin as biomarkers of HBOT effect in NSTI patients

Timeframe: At admission, and during the next 3 days in the ICU

suPAR as a biomarker of disease severity and prognosis in NSTI patients with and without septic shock

Timeframe: At admission

Trial details

NCT IDNCT03147352

SponsorOle Hyldegaard

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-01

View on ClinicalTrials.gov More Necrotizing Soft Tissue Infection trials